Telephone sharing button Contact Us linkedin sharing button Share wechat sharing button Share wechat sharing button Twitter mailbox sharing button info@wuxibiologics.com
arrow_left sharing button
arrow_right sharing button

Press Releases

WuXi AppTec Group Plans $120 Million Investment in New Integrated Biologics Solution Center to Expedite Biologics Development from Ideas to Clinic
Jan. 08, 2016
WuXi AppTec Group Plans $120 Million Investment in New Integrated Biologics Solution Center to Expedite Biologics Development from Ideas to Clinic

SHANGHAI, January 8, 2016 — WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced that it has started construction of a state-of-the-art integrated biologics solution center at the company’s headquarters in Shanghai. The company plans to invest a total of $120 million in this dedicated, 250,000-square-foot facility, which will be operational in 2017 and accommodate 800 scientists. The facility will provide integrated solutions from ideas to the clinic for biologics discovery, development, and clinical manufacturing on a consolidated campus.


The biologics discovery center will utilize the state-of-the-art OmniRat™ platform in collaboration with Open Monoclonal Technology, Inc., and in-house proprietary phage display libraries to enable global clients to discover conventional mAbs, bi-specific mAbs and antibody-drug conjugates. The biologics development center will utilize WuXi Biologics’ proprietary CHO cell line platform to develop robust fed-batch and perfusion processes to meet demanding processing needs. The co-located cGMP clinical manufacturing facilities will support four concurrent campaigns using 3x2000L fed-batch and 2x500L perfusion bioreactors. With this comprehensive platform integrated from discovery through all aspects of development, customers will benefit from the speed, agility, efficiency, and unsurpassed quality of WuXi Biologics’ operations to expedite their global biologics research and development.


“We are very pleased to continue to invest in our biologics capabilities and expand our capacities to support the ambitious plans of our global clients,” said Dr. Ge Li, Chairman of WuXi Biologics. “Through this investment, WuXi Biologics will further strengthen its position as a global leader in biologics R&D, offering a truly unique integrated solution.”

Notice:

You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?